Enhanced Regional CBF in Patients with Mild Alzheimer’s Disease after Three Months of Aricept® Treatment
نویسندگان
چکیده
W. Li, C. Xie, Z. Wu, J. Jones, P. Antuono, T. McRae, and S-J. Li Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States, Neurology, School of Clinical Medicine, Southeaset university, Nanjing, Jiang Su, China, People's Republic of, Neurology, Medical College of Wisconsin, Milwaukee, WI, United States, Pfizer, Inc., Psychiatry, Medical College of Wisconsin, Milwaukee, WI, United States
منابع مشابه
ARICEPT safely and effectively. See full prescribing information for ARICEPT Tablets and ARICEPT Orally Disintegrating Tablets (ODT). ARICEPT
----------------------------RECENT MAJOR CHANGES-------------------- Addition of new dosage strength: ARICEPT 23 mg ----------------------------INDICATIONS AND USAGE--------------------- ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease (1.0).
متن کاملIncreases in CBF by Donepezil treatment Enhance Cingulate Functional Network activity in Mild Alzheimerâ€TMs Disease
Introduction: Cholinergic inhibitor (Aricept®) has been shown to improve cognitive function in adults with Alzheimer’s disease (AD) [1]. Also, it has an effect on improving the cerebral blood flow (CBF) perfusion detected by PET technology [2]. Previously we have found increased CBF in cingulated and posterior cingulated regions using a Pseudo-Continuous Arterial Spin Labeling (pCASL) MR techni...
متن کاملARICEPT Tablets and ARICEPT Orally Disintegrating Tablets (ODT). ARICEPT
----------------------------RECENT MAJOR CHANGES-------------------- Addition of new dosage strength: ARICEPT 23 mg ----------------------------INDICATIONS AND USAGE--------------------- ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease (1.0).
متن کاملRivastigmine in the treatment of Alzheimer’s disease: an update
Alzheimer's disease is the most common form of dementia in industrialized countries. In the European Union, about 54% of dementia cases are believed to be due to Alzheimer's disease. The condition is an age-related neurodegenerative disorder characterized by multiple cognitive deficiencies, including loss of memory, judgment, and comprehension. These manifestations are accompanied by behavioral...
متن کاملUpdate on Cholinesterase Inhibitors and Treatment of Alzheimer’s Disease
The long-term studies of the cholinesterase inhibitors, Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine), support their ability to delay Alzheimer’s disease (AD) progression during the dementia stage by 1, 1.5, and 2.5 years respectively, which underscores the importance of early detection to optimize quality of life. Cholinesterase inhibitors reduce caregiving burden by de...
متن کامل